id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
S12862 R48541 |
Thomas (Valproate) (Controls exposed to Lamotrigine, sick), 2021 | Urinary malformations | 1st trimester | prospective cohort | exposed to other treatment, sick excluded | Adjustment: No |
0.43 [0.04;4.26] C excluded (control group) |
3/341 1/50 | 4 | 341 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S12864 R48553 |
Thomas (Valproate) (Controls unexposed, sick), 2021 | Urinary malformations | 1st trimester | prospective cohort | unexposed, sick | Adjustment: No | 0.49 [0.12;1.99] C | 3/341 6/340 | 9 | 341 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9359 R32740 |
Tomson (Valproate), 2018 | Renal malformations | at least 1st trimester | prospective cohort | exposed to other treatment, sick | Adjustment: No | 1.60 [0.58;4.41] C | 7/1,381 8/2,514 | 15 | 1,381 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9325 R32511 |
Veiby (Valproate) (Controls exposed to Lamotrigine, sick) (Mixed indications), 2014 | Urinary | throughout pregnancy | population based cohort retrospective | exposed to other treatment, sick | Adjustment: No | 1.25 [0.11;13.85] C | 1/333 2/833 | 3 | 333 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9330 R32544 |
Artama (Valproate), 2005 | Urinary system | 1st trimester | retrospective cohort (registry) | unexposed, sick | Adjustment: No | 3.58 [0.22;57.43] C | 1/263 1/939 | 2 | 263 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total | 4 studies | 1.18 [0.56;2.49] | 29 | 2,318 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives |
1: Valproate) (Controls unexposed, sick; 2: Valproate; 3: Valproate) (Controls exposed to Lamotrigine, sick) (Mixed indications; 4: Valproate;
Asymetry test p-value = NaN (by Egger's regression)
not enought points
excluded 12862